Skip to main content
. 2023 Apr 8;15(8):2204. doi: 10.3390/cancers15082204

Figure 3.

Figure 3

The FUTURE trial schema: integrating TNBC subtyping and genomic targeting. n, number of the patients; TNBC, triple-negative breast cancer; FUSCC, Fudan University Shanghai Cancer Center; LAR, luminal androgen receptor; IM, immunomodulatory; BLIS, basal-like immune-suppressed; MES, mesenchymal-like; AR, androgen receptor; PD-1, programmed cell death-1; PARPi, poly ADP-ribose polymerase inhibitor; VEGFR, vascular endothelial growth factor receptor (adapted from [136]).